Mysoline (Primidone) Patent Expiration, LOE Window & CMS Spending

Mysoline (Primidone) by Bausch Health: Off-Patent Genericized (AB Competition), 7 AB generics, $14.3M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBausch Health
FDA Application & PathwayN009170 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors7
2024 CMS Total Public Spend$14.3M
2024 Medicare Part D Spend$12.9M
2024 Medicaid Spend$1.4M
Reported Wholesale Price Change (CA SB 17)8 WAC filings (max 30.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.